Alterity Therapeutics is a groundbreaking brand that aims to create an alternate future for people living with neurodegenerative diseases. Their mission is to disrupt the accepted trajectory for these diseases, offering individuals a healthier and improved life. Operating since 1997, Alterity Therapeutics was initially incorporated as Prana Biotechnology and is based in Melbourne, Australia, with offices in San Francisco, USA.

They are listed on both the Australian Securities Exchange and NASDAQ, denoted by the ticker codes ASX: ATH and NASDAQ: ATHE. Led by a capable and accomplished management team, including Chief Executive Officer Dr. David Stamler, and Chief Financial Officer Kathryn Andrews, Alterity Therapeutics boasts a stellar lineup of executives who are dedicated to advancing the field of neurodegenerative disease treatment.

With their cutting-edge science and innovative approach, Alterity Therapeutics is poised to make a profound impact in the lives of those affected by these conditions